ISONIAZID

Isoniazid is a firstline antitubercular drug inhibiting mycolicacid synthesis. Side effects include hepatotoxicity, neuropathy, and rash. Only GMP materials will be supplied, logistics all according to GDP.

Product Description


Mechanism of Action

ISONIAZID exhibits complex multipathway biochemical interactions involving receptorlevel modulation, regulatory enzyme interference, intracellular signalling adjustment and transcriptomic pathway influence. Its physicochemical profile suggests affinity for catalytic and regulatory protein domains, enabling disruption or enhancement of phosphorylation cycles, redoxstate balance, and mitochondrial performance. In several experimental systems, the compound demonstrates capacity to alter calcium signalling, membrane potential, structuralprotein dynamics and cellular metabolic flux.

Benefits and Advantages

This compound supports highresolution biochemical modelling and is suitable for use in:

  • Receptorligand binding studies and pathway validation
  • Metabolicflux assays, mitochondrialstress evaluations and ROSregulation research
  • Multiomics profiling (transcriptomics, metabolomics, proteomics)
  • Stressresponse signalling, kinase/phosphatase cascade mapping and cytoskeletal dynamics analysis
  • Earlyphase pharmacodynamic screening and SAR exploration

Side Effects and Risks

Potential risks include redox imbalance, mitochondrial overload, cytoskeletal disruption, altered membrane integrity, aberrant calcium flux, and dosedependent cytotoxicity. At elevated concentrations, the compound may induce apoptosis, autophagy, or transcriptional stress responses. Use only under strict laboratory conditions with appropriate biosafety protocols and controlled exposure.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C6H7N3O2

Molecular Weight

137.14 g/mol

CAS Number

54-85-3

Storage Condition

Store below 40 °C (104 °C), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight, light-resistant container. Protect from freezing. NOTE: Crystallization may occur at low temperatures. Upon warming to room temperature, the crystals will redissolve.

Solubility

greater than or equal to 100 mg/mL at 77 °F (NTP, 1992)

Purity

Purity information is available upon request (COA).

Synonym

isoniazid; 54-85-3; Isonicotinic acid hydrazide; Isonicotinohydrazide; pyridine-4-carbohydrazide

IUPAC/Chemical Name

pyridine-4-carbohydrazide

InChl Key

QRXWMOHMRWLFEY-UHFFFAOYSA-N

InChl Code

InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)

References

https://pubchem.ncbi.nlm.nih.gov/compound/3767;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download